Rivaroxaban Versus Warfarin in Acute Ischemic Stroke With Atrial Fibrillation

PHASE2CompletedINTERVENTIONAL
Enrollment

195

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Ischemic StrokeTransient Ischemic Attack
Interventions
DRUG

Rivaroxaban

"Rivaroxaban group receive oral rivaroxaban 10 mg once daily for 5 consecutive days, followed by 20 mg or 15 mg in patients with a calculated creatinine clearance of 30-49 ml/min.~The dosage of rivaroxaban is leveraged from results of ROCKET-AF trial, where 20 mg of rivaroxaban was shown to offer balanced efficacy and safety."

DRUG

Warfarin

To harmonize the warfarin regimen across the sites, fixed algorithm was used in dose calculation, both loading and maintenance, and age, sex, ethnicity, race, weight, height, smoking history, presence of liver disease, indication, baseline INR, target INR and concomitant medication were considered as cofactors (http://www.warfarindosing.org/Source/InitialDose.aspx). Investigators will manage anticoagulation with warfarin per routine clinical care.

Trial Locations (1)

138-736

Asan Medical Center, Seoul

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

Asan Medical Center

OTHER